 | This article contains content that is written like an advertisement. (February 2022) |
 | |
 WuXi Biologics Headquarters in Shanghai (2021 Construction) | |
| Company type | Public |
|---|---|
| SEHK: 2269 Hang Seng Index Component | |
| ISIN | KYG970081173 |
| Industry | |
| Founded | 2015 in Wu Xi City, China |
| Headquarters | Primary: 108 Meiliang Road, Mashan, Binhu District, Wuxi, Jiangsu, China, 214092 |
Area served | Worldwide |
Key people |
|
| Parent | WuXi AppTec |
| Subsidiaries | WuXi Vaccines CMAB Biopharma Group |
| Website | www |
| Footnotes / references [1][2][3][4] | |
WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, and began building out capabilities and facilities required for biologics discovery, development and GMP manufacturing.[5] WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.[6]
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.[7]
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.[8]
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns.[9][10][11] The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy.[12] Members of the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party subsequently called for sanctions against WuXi Biologics.[13]
- ^ "Leadership". WuXi Biologics. Archived from the original on 2020-12-02. Retrieved 2020-12-06.
- ^ "Annual Financial Reports". WuXi Biologics. Archived from the original on 2020-12-02. Retrieved 2020-12-06.
- ^ "WuXi Vaccines Overviewlanguage=en-US". Archived from the original on 2020-12-03. Retrieved 2020-12-06.
- ^ "WuXi Biologics to acquire CMAB Biopharma Grouplanguage=en-US". Retrieved 2021-03-18.
- ^ "CHNA ETF Video Series: WuXi Biologics". loncarfunds.com. Archived from the original on 2019-08-14. Retrieved 2019-08-14.
- ^ "UPDATE 2-WuXi Biologics prices HK IPO at top as investors seek..." Reuters. 2017-06-06. Archived from the original on 2019-08-14. Retrieved 2019-08-14.
- ^ "Global Network". WuXi Press Release. 2020-12-06. Archived from the original on 2020-12-02. Retrieved 2020-12-06.
- ^ "Alibaba, Xiaomi, WuXi Biologics to join Hang Seng Index". S&P Global Market Intelligence. 2020-12-06. Archived from the original on 2023-01-10. Retrieved 2020-12-06.
- ^ "WuXi Bio Denies Military Ties After Shares Slumped on US Bill". Bloomberg News. 2024-01-29. Archived from the original on 2024-01-29. Retrieved 2024-01-30.
- ^ "WuXi AppTec Shares Continue Slide After Company Calls U.S. Draft Bill Findings Inaccurate". The Wall Street Journal. January 28, 2024. Archived from the original on January 29, 2024. Retrieved January 29, 2024.
- ^ "WuXi Company Shares Tumble on U.S. Bill Aimed at Chinese Biotech". The Wall Street Journal. February 2, 2024. Archived from the original on February 1, 2024. Retrieved February 2, 2024.
- ^ Cheung, Sunny; Hope, Arran; Mattis, Peter (February 9, 2024). "Red Genes: Assessing WuXi AppTec's Ties to the Party-Army-State in China". Jamestown Foundation. Archived from the original on 2024-02-10. Retrieved 2024-02-11.
- ^ Martina, Michael (February 12, 2024). "US lawmakers call for sanctions on China's WuXi AppTec biotech firm". Reuters. Retrieved February 12, 2024.